Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2011

Open Access 01-12-2011 | Research article

Self-reported responsiveness to direct-to-consumer drug advertising and medication use: results of a national survey

Authors: Nicholas J Dieringer, Lisa Kukkamma, Grant W Somes, Ronald I Shorr

Published in: BMC Health Services Research | Issue 1/2011

Login to get access

Abstract

Background

Direct-to-consumer (DTC) marketing of pharmaceuticals is controversial, yet effective. Little is known relating patterns of medication use to patient responsiveness to DTC.

Methods

We conducted a secondary analysis of data collected in national telephone survey on knowledge of and attitudes toward DTC advertisements. The survey of 1081 U.S. adults (response rate = 65%) was conducted by the Food and Drug Administration (FDA). Responsiveness to DTC was defined as an affirmative response to the item: "Has an advertisement for a prescription drug ever caused you to ask a doctor about a medical condition or illness of your own that you had not talked to a doctor about before?" Patients reported number of prescription and over-the-counter (OTC) medicines taken as well as demographic and personal health information.

Results

Of 771 respondents who met study criteria, 195 (25%) were responsive to DTC. Only 7% respondents taking no prescription were responsive, whereas 45% of respondents taking 5 or more prescription medications were responsive. This trend remained significant (p trend .0009) even when controlling for age, gender, race, educational attainment, income, self-reported health status, and whether respondents "liked" DTC advertising. There was no relationship between the number of OTC medications taken and the propensity to discuss health-related problems in response to DTC advertisements (p = .4).

Conclusion

There is a strong cross-sectional relationship between the number of prescription, but not OTC, drugs used and responsiveness to DTC advertising. Although this relationship could be explained by physician compliance with patient requests for medications, it is also plausible that DTC advertisements have a particular appeal to patients prone to taking multiple medications. Outpatients motivated to discuss medical conditions based on their exposure to DTC advertising may require a careful medication history to evaluate for therapeutic duplication or overmedication.
Appendix
Available only for authorised users
Literature
1.
Holmer AF: Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999, 281: 380-382. 10.1001/jama.281.4.380.CrossRefPubMed
2.
Rados C: Truth in Advertising: Rx Drug Ads Come of Age. FDA Consum. 2004, 38 (4): 20-27.
3.
Wilkes MS, Bell RA, Kravitz RL: Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood). 2000, 19: 110-128. 10.1377/hlthaff.19.2.110.CrossRef
4.
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM: Promotion of prescription drugs to consumers. N Engl J Med. 2002, 346: 498-505. 10.1056/NEJMsa012075.CrossRefPubMed
5.
6.
Donohue JM, Cevasco M, Rosenthal MB: A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007, 357: 673-681. 10.1056/NEJMsa070502.CrossRefPubMed
7.
8.
Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. (GAO-03-177). 2002, Washington, D.C.: United States General Accounting Office
9.
Bell RA, Kravitz RL, Wilkes MS: Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999, 14: 651-657. 10.1046/j.1525-1497.1999.01049.x.CrossRefPubMedPubMedCentral
10.
Robinson AR, Hohmann KB, Rifkin JI, Topp D, Gilroy CM, Pickard JA, Anderson RJ: Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med. 2004, 164: 427-432. 10.1001/archinte.164.4.427.CrossRefPubMed
11.
12.
Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P: Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005, 293: 1995-2002. 10.1001/jama.293.16.1995.CrossRefPubMedPubMedCentral
13.
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002, 324: 278-279. 10.1136/bmj.324.7332.278.CrossRefPubMedPubMedCentral
14.
Murray E, Lo B, Pollack L, Donelan K, Lee K: Direct-to-consumer advertising: public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship. J Am Board Fam Pract. 2004, 17: 6-18. 10.3122/jabfm.17.1.6.CrossRefPubMed
15.
Schommer JC, Singh RL, Hansen RA: Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisements. Res Social Adm Pharm. 2005, 1: 231-250. 10.1016/j.sapharm.2005.03.009.CrossRefPubMed
16.
Khanfar N, Loudon D, Sircar-Ramsewak F: FDA direct-to-consumer advertising for prescription drugs: what are consumer preferences and response tendencies?. Health Mark Q. 2007, 24: 77-91. 10.1080/07359680802125899.CrossRefPubMed
17.
Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S: Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff (Millwood). 2004, W4-33. Suppl Web Exclusives
18.
Lee D, Begley CE: Racial and ethnic disparities in response to direct-to-consumer advertising. Am J Health Syst Pharm. 2010, 67: 1185-1190. 10.2146/ajhp090600.CrossRefPubMed
19.
Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG: Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf. 2006, 15: 710-718. 10.1002/pds.1226.CrossRefPubMed
20.
Caskie GI, Willis SL: Congruence of self-reported medications with pharmacy prescription records in low-income older adults. Gerontologist. 2004, 44: 176-185. 10.1093/geront/44.2.176.CrossRefPubMedPubMedCentral
Metadata
Title
Self-reported responsiveness to direct-to-consumer drug advertising and medication use: results of a national survey
Authors
Nicholas J Dieringer
Lisa Kukkamma
Grant W Somes
Ronald I Shorr
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2011
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-11-232

Other articles of this Issue 1/2011

BMC Health Services Research 1/2011 Go to the issue

Research article

Predicting mortality of residents at admission to nursing home: A longitudinal cohort study

Study protocol

The effectiveness of the Liverpool care pathway in improving end of life care for dying cancer patients in hospital. A cluster randomised trial

Study protocol

Evaluating an in-home multicomponent cognitive behavioural programme to manage concerns about falls and associated activity avoidance in frail community-dwelling older people: Design of a randomised control trial [NCT01358032]

Research article

What stops children with a chronic illness accessing health care: a mixed methods study in children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)

Research article

DRG coding practice: a nationwide hospital survey in Thailand

Research article

Childhood tuberculosis deskguide and monitoring: An intervention to improve case management in Pakistan